OSLO--(BUSINESS WIRE)--The Norwegian pharmaceutical company Lytix Biopharma AS provided an update at the recent BIO conference in Chicago on Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.
OSLO--(BUSINESS WIRE)--The Norwegian pharmaceutical company Lytix Biopharma AS provided an update at the recent BIO conference in Chicago on Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.
